Clinical efficacy of recombinant human thrombopoietin combined with glucocorticoids in the treatment of immune thrombocytopenia

Figures & data

Table 1. Comparison of baseline data between two groups (n, $\overline{\chi }$ ±S).

Group	Sex (Male/Female)	Age (years)	Duration of disease (years)	BMI (kg/m^2)	Disease staging (newly diagnosed/persistent/chronic)	Bleeding site (skin/mouth/nose/urinary tract/others)
Control group (n = 42)	26/16	56.39 ± 4.84	4.12 ± 1.67	23.39 ± 2.24	0/5/37	31/12/13/15/6
Study group (n = 45)	30/15	56.89 ± 4.75	4.25 ± 1.43	23.27 ± 2.17	0/8/37	35/14/15/16/5

Table 2. Comparison of clinical efficacy (n)%.

Group	Markedly effective	Effective	Ineffective	Total effective
Control group (n = 42)	17 (40.48)	15 (35.71)	10 (23.81)	32 (76.19)
Study group (n = 45)	23 (51.11)	20 (44.44)	2 (4.44)	43 (95.56)
χ2	–	–	–	6.851
P	–	–	-P	0.009

Table 3. Comparison of the time to PLT > 50*10⁹/L, the number of platelet transfusions and bleeding score in both groups ($\overline{\chi }$±S).

Group	Time to PLT > 50*10^9/L (d)	Number of platelet transfusion (times)	Bleeding score
			Before treatment	After treatment
Control group (n = 42)	13.48 ± 2.14	1.98 ± 0.51	5.48 ± 2.17	2.91 ± 1.83^###
Study group (n = 45)	9.25 ± 2.06***	0.85 ± 0.35***	5.27 ± 2.26	2.09 ± 1.67^###*

Note: Compared to before treatment, ^###P < 0.001; Compared to the control group, *P < 0.05, ***P < 0.001

Table 4. Comparison of PLT before and after treatment between the two groups ($\overline{\chi }$±S, *109/L).

Group	Before treatment	1d after treatment	7d after treatment	14d after treatment
Control group (n = 42)	11.25 ± 3.59	20.05 ± 2.51	42.98 ± 5.51	118.25 ± 10.25
Study group (n = 45)	11.59 ± 3.25	23.51 ± 3.19***	58.85 ± 4.35***	136.25 ± 11.02***

Note: Compared to the control group, ***P < 0.001

Figure 1. Comparison of changes in T lymphocyte subpopulations between the two groups.

Figure 1 shows that rhTPO combined with glucocorticoid treatment significantly increases (A) CD3+, (B) CD4+, (D) CD4+/CD8+ levels, and decreases (C) CD8 + levels, suggesting that rhTPO combined with glucocorticoids could improve the immune function of patients. Note: Compared with the control group, ***P < 0.001; compared within the same group before treatment, ^###P < 0.001. rhTPO, recombinant human thrombopoietin.

Figure 2. Comparison of the changes in coagulation function between the two groups.

Figure 2 shows that the differences in (A) PT, (B) FIB, and (C) APTT between the two groups are not statistically significant before and after rhTPO combined with glucocorticoid therapy, suggesting that rhTPO combined with glucocorticoids did not affect the coagulation function of patients. APTT, activated partial thromboplastin time; FB, fibrinogen; PT, prothrombin time; rhTPO, recombinant human thrombopoietin.

Table 5. Comparison of adverse reactions between two groups (n)%.

Group	Muscle aches and pains	Dizziness	Nausea and vomiting	Fever	Total
Control group (n = 42)	1 (2.38)	0	1 (2.38)	0	2 (4.76)
Study group (n = 45)	1 (2.22)	1 (2.22)	1 (2.22)	1 (2.22)	4 (8.89)